3 Topic Commentaries

ASCO 2026: FDA-Cleared AI Put to the Test

ASCO 2026: FDA-Cleared AI Put to the Test

• 

  Chadi Nabhan, MD, MBA, FACP

  Oncology

  •

  Ryght AI

  Too many metastatic breast cancer trials lose precious months in slow, manual and error-prone site selection processes. Our mission at Ryght is to transform clinical trial timelines by giving research sponsors and networks like ASCO an AI-driven platform that quickly surfaces the right sites for the right studies. When trials open sooner at better sites, patients gain access to innovative therapies at a crucial time, and that is what matters most.

  Source
• 

  Julian Hong, MD, MS

  Radiation Oncology

  •

  University of California, San Francisco

  Accurate HER2 scoring is important to ensure that patients receive the best treatment for their breast cancer. This international study shows that an AI-assisted approach improved HER2 scoring, including in situations that would affect treatment decisions. These findings shed light on the promising role for AI in oncology, not as a replacement for the physician, but as a powerful tool to help us work smarter and faster to deliver high-quality, more personalized care.

  Source
• 

  Clifford A. Hudis, MD, FACP, FASCO

  Medical Oncology

  •

  American Society of Clinical Oncology (ASCO)

  AI is transforming cancer care at an incredible rate, but the amount of noise in the AI space can be distracting or confusing. This resource cuts through that noise by delivering useful insights directly from trusted oncology experts. Translating these insights into practical tips can help clinicians confidently use AI to prioritize what matters most: patient outcomes.

  Source